Low-versus high-dose rituximab for antibody-mediated rejection after kidney transplantation

Transplant International

Volumn 26, Issue 2, 2013, Pages

  Bellière, Julie ^a   Rostaing, Lionel ^a,b,c   Guilbeau Frugier, Céline ^a,c   Congy, Nicolas ^a,c   Kamar, Nassim ^a,b,c  

^a Dialysis and Organ Transplantation ^*  (France)

^b University of Toulouse III   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MYCOPHENOLIC ACID; OKT 3; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872600917     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12015     Document Type: Letter

References (6)

1. Becker YT, Becker BN, Pirsch JD, Sollinger HW,. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996.
2. Rostaing L, Guilbeaud-Frugier C, Kamar N,. Rituximab for humoral rejection after kidney transplantation: an update. Transplantation 2009; 87: 1261.
3. Mulley WR, Hudson FJ, Tait BD, et al,. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009; 87: 286.
4. Kamar N, Milioto O, Puissant-Lubrano B, et al,. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89.
5. Fehr T, Gaspert A,. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 2012; 25: 623.
6. Lefaucheur C, Nochy D, Andrade J, et al,. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.